The ROE as of December 2024 (TTM) for Annovis Bio, Inc. (ANVS) is 874.76%

According to Annovis Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is 874.76%. This represents a change of -2062.29% compared to the average of -44578.66% of the last 4 quarters.

Annovis Bio, Inc. (ANVS) Historical ROE (quarterly & annually)

How has ANVS ROE performed in the past?

The mean historical ROE of Annovis Bio, Inc. over the last ten years is 81.44%. The current 874.76% ROE has changed 1.07% with respect to the historical average. Over the past ten years (40 quarters), ANVS's ROE was at its highest in in the June 2024 quarter at 286.74%. The ROE was at its lowest in in the September 2024 quarter at -178919.79%.

Annovis Bio, Inc. (ANVS) ROE by Quarter and Year

Discovering the peaks and valleys of Annovis Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Annovis Bio, Inc. (ANVS) Average ROE

How has ANVS ROE performed in the past?

The current ROE of Annovis Bio, Inc. (ANVS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Annovis Bio, Inc. (ANVS) ROE vs. Peers

How is ANVS’s ROE compared to its peers?

Annovis Bio, Inc.’s ROE is greater than Cassava Sciences, Inc. (-12.36%), greater than Axsome Therapeutics, Inc. (-234.35%), greater than Reviva Pharmaceuticals Holdings, Inc. (1.15%), greater than Seres Therapeutics, Inc. (60.75%), greater than Anavex Life Sciences Corp. (-30.63%), greater than Iovance Biotherapeutics, Inc. (-58.43%), greater than Novavax, Inc. (44.82%), greater than Anixa Biosciences, Inc. (-52.41%), greater than TFF Pharmaceuticals, Inc. (-310.17%), greater than Immunome, Inc. (-139.72%), greater than IN8bio, Inc. (-197.15%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Galera Therapeutics, Inc. (14.34%), greater than Cue Biopharma, Inc. (-156.38%), greater than Lantern Pharma Inc. (-56.90%), greater than Gracell Biotechnologies Inc. (-15.56%),

Build a custom stock screener for Annovis Bio, Inc. (ANVS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Annovis Bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Annovis Bio, Inc. (ANVS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Annovis Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.